ArticleDiscover oncology2025
In silico analysis of the oncogenic role of myoferlin (MYOF) and suggestion of folate as a potential therapeutic for brain cancer in the Caucasian population.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyoferlin (MYOF), a key gene in endocytosis, is known to be crucial for metastasis in cancer. While the involvement of MYOF as a biomarker is documented in cancer, a comprehensive study on its knockdown for targeted therapy via folate is a novel approach.
methodsIn the current study, the expression, pathways, mutations, and interacting genes of MYOF were analyzed via bioinformatics analysis, which included computational drug discovery and spatial transcriptomics coupled with generative artificial intelligence experiments that were performed to elucidate the role of folate in MYOF knockdown.
resultsThe findings identified MYOF as a predominantly expressed gene biomarker in brain cancer genesis and its progression. Literature-reported mutations of MYOF were linked to pathways associated with depression, reinforcing the connection between brain cancer, tyrosine mutations, and depression in Caucasian patients. Additionally, computational drug discovery and spatial transcriptomics involving generative artificial intelligence experiments demonstrated folate as a potential therapeutic in MYOF knockdown.
conclusionsThese results suggest that dysregulation and mutation of MYOF position it as an oncogenic factor, and it serves as a potential therapeutic target for folate therapy for brain cancer associated with Caucasians.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.